AA
MACK

ALPS Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

ALPS Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-21,889
Closed -$14.7K – 710
2015
Q3 		$14.7K Buy
21,889
+8,008
+58% +$654K 0.02% 187
2015
Q2 		$1.35M Buy
13,881
+7,196
+108% +$685K 0.01% 192
2015
Q1 		$625K Buy
+6,685
New +$569K 0.01% 209

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

ALPS Advisors's MACK Position: Q4 2015 in Review

ALPS Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2015, closing a stake of 21,889 shares — an estimated $14.7K sold.

ALPS Advisors first reported a position in MACK in Q1 2015 and held it in 3 quarters. The position peaked at $1.35M in Q2 2015. 139 funds tracked by Wall St. Rank hold MACK as of Q4 2015.

  • ALPS Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • ALPS Advisors sold 21,889 Merrimack Pharmaceuticals, Inc. shares in Q4 2015, an estimated $14.7K.
  • ALPS Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2015 and held it in 3 quarters.
  • ALPS Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $1.35M in Q2 2015.
  • 139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2015.

Based on ALPS Advisors's 13F filing for Q4 2015, filed 5 Feb 2016.